Whole-blood transcriptomics reveal molecular compatibility and complementarity across advanced therapies in ulcerative colitis
Authors: Alsoud, Dahham; Abdurahiman, Saeed; Sabino, Joao; Ferrante, Marc; Vermeire, Severine; Verstockt, Bram
Source journal: Journal of Crohn's & colitis (2026-11-07)
Abstract
BACKGROUND AND AIMS: Despite an expanding therapeutic landscape, an efficacy ceiling persists with advanced monotherapies in ulcerative colitis (UC). We used longitudinal whole-blood transcriptomics to characterize molecular compatibility, therapy-specific effects with potential complementarity, and potential cross-therapy resistance correction. METHODS: Adults with endoscopically active UC (Mayo endoscopic sub-score [MES] >/=2) initiating anti-tumor necrosis factor (anti-TNF), vedolizumab (VDZ), tofacitinib (TFC), or ustekinumab (UST) underwent whole-blood RNA sequencing at baseline and/or post-induction endoscopy. Endoscopic improvement was defined as MES /=50% of the corresponding resistance effect. RESULTS: Among 314 treatment cycles from 234 patients (514 RNA samples), 47.6% achieved endoscopic improvement. Anti-TNF, VDZ, and TFC response-associated signatures were broadly concordant across molecular layers while retaining therapy-specific features. UST showed no significant response-associated DEGs but retained distinct pathway- and TF-level signals. In parallel, cross-therapy response-associated effects opposed resistance-associated features, with correlations of -0.89 to -1.00 for genes, -0.64 to -0.84 for biological processes, and -0.52 to -0.76 for TF activities. Against anti-TNF resistance, VDZ met the potential-correction criterion for 70% of DEGs, 79% of biological processes, and 96% of TF activities, including all 20 resistance processes with the largest absolute enrichment scores. CONCLUSIONS: Whole-blood transcriptomics identified compatible shared responses, therapy-specific molecular effects, and potential cross-therapy compensation. These findings generate hypotheses for biologically informed combination strategies requiring prospective validation, rather than evidence of efficacy or synergy.
Related topics
Related open access articles
- The Differentiation and Roles of inflammatory Cytokine in the initiation of Inflammatory Bowel Diseases (IBD)
- The Regulations of Gene Expressions by 1α,25(OH)2D3 in Patients with Inflammatory Bowel Diseases
- PROFILE OF INTERLEUKIN-1β IN CERVICAL CANCER PATIENTS ATTENDING ONCOLOGY UNIT, USMANU DANFODIYO UNIVERSITY TEACHING HOSPITAL, SOKOTO-NIGERIA.
- Interaction profiling of growth hormone receptor and growth hormone proteins in Labeo rohita: an insight using molecular modelling and docking approaches
- Identification of ‘stress and Ca ++ metabolism related gene expression’ in wild Peromyscus exposed to environmental lead using combinatorial data from Mus cDNA microarrays and blood metabolites
- microRNA expression profiling in human diploid cells infected with enterovirus 71 or coxsackievirus A16
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.